BRPI0918947A2 - proteína de fusão de anticorpo - Google Patents

proteína de fusão de anticorpo

Info

Publication number: BRPI0918947A2
Authority: BR; Brazil
Prior art keywords: fusion protein; antibody fusion; antibody; protein; fusion
Prior art date: 2008-09-26

Application number

BRPI0918947A

Other languages

English (en)

Inventor

Laura Hancock

Ralph Adams

Sam Philip Heywood

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-26

Filing date

2009-09-25

Publication date

2015-12-01

2008-09-26 Priority claimed from GB0817704A external-priority patent/GB0817704D0/en

2009-03-26 Priority claimed from GB0905314A external-priority patent/GB0905314D0/en

2009-09-25 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2015-12-01 Publication of BRPI0918947A2 publication Critical patent/BRPI0918947A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

BRPI0918947A 2008-09-26 2009-09-25 proteína de fusão de anticorpo BRPI0918947A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0817704A GB0817704D0 (en)	2008-09-26	2008-09-26	Biological products
GB0905314A GB0905314D0 (en)	2009-03-26	2009-03-26	Biological products
PCT/GB2009/002310 WO2010035012A1 (en)	2008-09-26	2009-09-25	Biological products

Publications (1)

Publication Number	Publication Date
BRPI0918947A2 true BRPI0918947A2 (pt)	2015-12-01

Family

ID=41664777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918947A BRPI0918947A2 (pt)	2008-09-26	2009-09-25	proteína de fusão de anticorpo

Country Status (17)

Country	Link
US (2)	US10407513B2 (pt)
EP (1)	EP2334705B1 (pt)
JP (2)	JP6063122B2 (pt)
CN (2)	CN102164965B (pt)
BR (1)	BRPI0918947A2 (pt)
CA (1)	CA2737241C (pt)
CY (1)	CY1118713T1 (pt)
DK (1)	DK2334705T3 (pt)
EA (1)	EA201100527A1 (pt)
ES (1)	ES2620603T3 (pt)
HR (1)	HRP20170374T1 (pt)
HU (1)	HUE033438T2 (pt)
LT (1)	LT2334705T (pt)
PL (1)	PL2334705T3 (pt)
PT (1)	PT2334705T (pt)
SI (1)	SI2334705T1 (pt)
WO (1)	WO2010035012A1 (pt)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2667729T3 (es) *	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
JP5616428B2 (ja)	2009-04-07	2014-10-29	ロシュグリクアートアクチェンゲゼルシャフト	三価の二重特異性抗体
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
WO2011030107A1 (en)	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
GB201005063D0 (en) *	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US9234037B2 (en)	2009-10-27	2016-01-12	Ucb Biopharma Sprl	Method to generate antibodies to ion channels
GB0922435D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	Method
GB0922434D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
EP2493926B1 (en)	2009-10-27	2020-03-11	UCB Biopharma SRL	Function modifying nav 1.7 antibodies
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
GB0920324D0 (en) *	2009-11-19	2010-01-06	Ucb Pharma Sa	Antibodies
TW201134488A (en)	2010-03-11	2011-10-16	Ucb Pharma Sa	PD-1 antibodies
US20130115215A1 (en) *	2010-07-14	2013-05-09	Hongxing Zhou	Domain insertion immunoglobulin
KR101612999B1 (ko) *	2010-08-24	2016-04-15	로슈 글리카트 아게	활성화가능 이중특이적 항체
EP2609111B1 (en) *	2010-08-24	2017-11-01	F. Hoffmann-La Roche AG	Bispecific antibodies comprising a disulfide stabilized-fv fragment
US9598499B2 (en)	2010-12-30	2017-03-21	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Antigen binding formats for use in therapeutic treatments or diagnostic assays
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
CN103384682B (zh)	2011-01-14	2017-04-12	Ucb医药有限公司	结合il‑17a和il‑17f的抗体分子
AU2012211011A1 (en) *	2011-01-28	2013-08-15	National Research Council Of Canada	Engineering of immunoglobulin domains
CN103619876A (zh) *	2011-03-10	2014-03-05	Hco抗体股份有限公司	双特异性三链抗体样分子
US9366677B2 (en) *	2011-09-06	2016-06-14	Max-Planck-Gesellshaft Zur Foerderung Der Wissenschaften E.V.	Methods for analyzing biological macromolecular complexes and use thereof
SI2758432T1 (sl)	2011-09-16	2019-07-31	Ucb Biopharma Sprl	Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
UA112203C2 (uk)	2011-11-11	2016-08-10	Юсб Фарма С.А.	Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CN103946237B (zh)	2011-11-11	2017-04-12	Ucb医药有限公司	白蛋白结合抗体及其结合片段
GB201208370D0 (en)	2012-05-14	2012-06-27	Ucb Pharma Sa	Antibodies
GB201208367D0 (en)	2012-05-14	2012-06-27	Ucb Pharma Sa	Biological product
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko)	2012-06-27	2015-03-20	에프. 호프만-라 로슈 아게	표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
US20160122436A1 (en) *	2013-03-15	2016-05-05	Amgen Research (Munich) Gmbh	Single chain binding molecules comprising n-terminal abp
GB201315487D0 (en)	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
WO2015030539A1 (en) *	2013-08-30	2015-03-05	Aprilbio Co., Ltd	An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
PL3021859T3 (pl)	2013-10-25	2018-06-29	Psioxus Therapeutics Limited	Adenowirusy onkolityczne wyposażone w geny heterolityczne
KR102551410B1 (ko)	2013-11-11	2023-07-04	추가이 세이야쿠 가부시키가이샤	개변된 항체 가변영역을 포함하는 항원 결합 분자
GB201320066D0 (en)	2013-11-13	2013-12-25	Ucb Pharma Sa	Biological products
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
GEP20196970B (en) *	2014-02-24	2019-04-25	Gmbh Takeda	Uti fusion proteins
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
GB201406608D0 (en)	2014-04-12	2014-05-28	Psioxus Therapeutics Ltd	Virus
GB201409558D0 (en)	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
TWI880146B (zh)	2014-11-11	2025-04-11	日商中外製藥股份有限公司	包含經改變之抗體可變區之抗原結合分子的資料庫
JP6721590B2 (ja)	2014-12-03	2020-07-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性抗体
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506869D0 (en) *	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
KR20170138570A (ko)	2015-04-30	2017-12-15	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
GB201508180D0 (en)	2015-05-13	2015-06-24	Ucb Biopharma Sprl	Antibodies
EP3303390A1 (en)	2015-05-27	2018-04-11	UCB Biopharma SPRL	Method for the treatment of neurological disease
WO2016192613A1 (zh) *	2015-06-01	2016-12-08	中山大学	具有融合至常规Fab片段的单域抗原结合片段的二价抗体
KR102770650B1 (ko)	2015-07-06	2025-02-19	유씨비 바이오파마 에스알엘	타우 결합 항체
EP3319984A1 (en)	2015-07-06	2018-05-16	UCB Biopharma SPRL	Tau-binding antibodies
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
ES2885476T3 (es)	2015-10-05	2021-12-13	Ucb Biopharma Sprl	Firmas moleculares para uso en diagnóstico y análisis de respuesta al tratamiento de enfermedades autoinmunes
SG11201802887PA (en)	2015-10-27	2018-05-30	Ucb Biopharma Sprl	Methods of treatment using anti-il-17a/f antibodies
GB201521393D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521383D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl And Ucb Celltech	Method
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521391D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
GB201602414D0 (en)	2016-02-10	2016-03-23	Nascient Ltd	Biological materials and uses thereof
BR112018071288A2 (pt) *	2016-05-01	2019-02-26	Ucb Biopharma Sprl	dominio de ligação de carreador de proteína sérica de afinidade modificada
GB201610198D0 (en)	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
SG11201810509PA (en)	2016-06-20	2018-12-28	Kymab Ltd	Anti-pd-l1 antibodies
IL264902B2 (en)	2016-08-29	2023-11-01	Akamis Bio Ltd	Adenovirus with bispecific T cell activator
WO2018083258A1 (en)	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding at least three transgenes
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018083257A1 (en)	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding transgenes
KR20230061582A (ko)	2016-12-07	2023-05-08	아블린쓰 엔.브이.	개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
SG10202108973SA (en) *	2017-01-17	2021-09-29	Ablynx Nv	Improved serum albumin binders
CN117285623A (zh) *	2017-01-17	2023-12-26	埃博灵克斯股份有限公司	改进的血清白蛋白结合物
WO2018183366A1 (en)	2017-03-28	2018-10-04	Syndax Pharmaceuticals, Inc.	Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018213665A1 (en)	2017-05-19	2018-11-22	Syndax Pharmaceuticals, Inc.	Combination therapies
LT3630143T (lt)	2017-06-01	2023-09-25	Akamis Bio Limited	Onkolitinis virusas ir būdas
WO2018224439A1 (en) *	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-hsa antibodies
JP7130678B2 (ja) *	2017-06-05	2022-09-05	ヌマブセラピューティクスアクチェンゲゼルシャフト	新規抗ｈｓａ抗体
US20200165347A1 (en)	2017-06-30	2020-05-28	Aslan Pharmaceuticals Pte Ltd	Method of treatment using il-13r antibody
EP3470426A1 (en)	2017-10-10	2019-04-17	Numab Therapeutics AG	Multispecific antibody
CA3075969A1 (en)	2017-10-10	2019-04-18	Numab Therapeutics AG	Multispecific antibody
US11952422B2 (en)	2017-12-05	2024-04-09	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3728328B1 (en)	2017-12-22	2024-10-23	Argenx BVBA	Bispecific antigen binding construct
GB201802487D0 (en)	2018-02-15	2018-04-04	Argenx Bvba	Cytokine combination therapy
EP3794017A4 (en)	2018-05-17	2022-03-09	Lumen Bioscience, Inc.	ARTHROSPIRA PLATENSIS ORAL VACCINE DELIVERY PLATFORM
GB201811368D0 (en)	2018-07-11	2018-08-29	Ucb Biopharma Sprl	Antibody
WO2020018586A1 (en)	2018-07-16	2020-01-23	Lumen Bioscience, Inc.	Thermostable phycobiliproteins produced in spirulina
MX2021000827A (es)	2018-08-03	2021-03-25	Chugai Pharmaceutical Co Ltd	Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
MX2021001902A (es)	2018-08-21	2021-05-27	Citryll B V	Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
JP2022501325A (ja) *	2018-09-28	2022-01-06	中外製薬株式会社	改変された抗体可変領域を含む抗原結合分子
CA3116091A1 (en)	2018-10-16	2020-04-23	UCB Biopharma SRL	Method for the treatment of myasthenia gravis
GB201817309D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
GB201817311D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
GB2596411B (en) *	2018-10-29	2023-09-20	Tigatx Inc	Compositions and methods comprising IgA antibody constructs
WO2020197502A1 (en)	2019-03-26	2020-10-01	Aslan Pharmaceuticals Pte Ltd	Treatment employing anti-il-13r antibody or binding fragment thereof
EP3947441A1 (en)	2019-03-27	2022-02-09	UMC Utrecht Holding B.V.	Engineered iga antibodies and methods of use
KR20250156861A (ko)	2019-05-21	2025-11-03	노파르티스 아게	Cd19 결합 분자 및 이의 용도
MA56463A (fr)	2019-07-03	2022-05-11	Lumen Bioscience Inc	Plate-forme d'administration non parentérale d'agent thérapeutique d'arthrospira platensis
EP3816185A1 (en)	2019-11-04	2021-05-05	Numab Therapeutics AG	Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
GB201919058D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibodies
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
KR20210095781A (ko)	2020-01-24	2021-08-03	주식회사 에이프릴바이오	항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
GB202001447D0 (en)	2020-02-03	2020-03-18	Ucb Biopharma Sprl	Antibodies
US20230192900A1 (en)	2020-02-13	2023-06-22	UCB Biopharma SRL	Bispecific antibodies binding hvem and cd9
EP4103612A1 (en)	2020-02-13	2022-12-21	UCB Biopharma SRL	Bispecific antibodies against cd9
US20230125234A1 (en)	2020-02-13	2023-04-27	UCB Biopharma SRL	Anti cd44-ctla4 bispecific antibodies
WO2021160267A1 (en)	2020-02-13	2021-08-19	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd7
US20230151108A1 (en)	2020-02-13	2023-05-18	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd137
KR20220143869A (ko)	2020-02-21	2022-10-25	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
BR112022019047A2 (pt)	2020-03-27	2022-11-01	UCB Biopharma SRL	Peptídeos de domínio knob autônomos
PE20230077A1 (es)	2020-03-31	2023-01-11	Chugai Pharmaceutical Co Ltd	Moleculas de union al antigeno multiespecificas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
TW202144429A (zh)	2020-05-14	2021-12-01	大陸商江蘇恆瑞醫藥股份有限公司	抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途
EP3915580A1 (en)	2020-05-29	2021-12-01	Numab Therapeutics AG	Multispecific antibody
TWI806087B (zh) *	2020-06-30	2023-06-21	大陸商和鉑醫藥（上海）有限責任公司	免疫細胞銜接多特異性結合蛋白及其製備和應用
MX2022015959A (es)	2020-07-02	2023-01-24	Beijing Tuo Jie Biopharmaceutical Co Ltd	Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
WO2022022508A1 (zh)	2020-07-27	2022-02-03	上海拓界生物医药科技有限公司	抗cd79b抗体药物偶联物、其制备方法及其医药用途
GB202012326D0 (en)	2020-08-07	2020-09-23	Citryll B V	Diagnostic
AU2021359092A1 (en)	2020-10-15	2023-06-01	UCB Biopharma SRL	Binding molecules that multimerise cd45
EP3988568A1 (en)	2020-10-21	2022-04-27	Numab Therapeutics AG	Combination treatment
US20230406924A1 (en)	2020-11-02	2023-12-21	UCB Biopharma SRL	Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
IL303295A (en)	2020-12-07	2023-07-01	UCB Biopharma SRL	Multi-specific antibodies and antibody combinations
AU2021398385A1 (en)	2020-12-07	2023-07-13	UCB Biopharma SRL	Antibodies against interleukin-22
WO2022140696A1 (en) *	2020-12-23	2022-06-30	Lumen Bioscience, Inc.	CONSTRUCTS COMPRISING SINGLE DOMAIN VHH ANTIBODIES AGAINST SARS-CoV-2
MX2023009022A (es)	2021-02-02	2023-10-23	Numab Therapeutics AG	Anticuerpos multiespecificos con especificidad para ror1 y cd3.
GB202102227D0 (en)	2021-02-17	2021-03-31	UCB Biopharma SRL	Antibodies
JP2024518724A (ja)	2021-04-25	2024-05-02	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
WO2022233764A1 (en)	2021-05-03	2022-11-10	UCB Biopharma SRL	Antibodies
EP4085973A1 (en)	2021-05-04	2022-11-09	Citryll B.V.	Inhibition of eosinophil extracellular traps
KR20240005856A (ko)	2021-05-04	2024-01-12	씨트릴 비.브이.	세포 외 트랩 억제
JP2024523514A (ja)	2021-06-28	2024-06-28	江蘇恒瑞医薬股▲ふん▼有限公司	抗ｃｄ４０抗体、その抗原結合断片及び医薬用途
GB202111905D0 (en)	2021-08-19	2021-10-06	UCB Biopharma SRL	Antibodies
WO2023025249A1 (zh)	2021-08-25	2023-03-02	江苏恒瑞医药股份有限公司	一种含融合蛋白的药物组合物
EP4403574A4 (en)	2021-09-15	2025-10-29	Jiangsu Hengrui Pharmaceuticals Co Ltd	PD-1-Specific Protein and Its Pharmaceutical Use
WO2023075702A1 (en)	2021-10-29	2023-05-04	Aslan Pharmaceuticals Pte Ltd	Anti-il-13r antibody formulation
EP4183800A1 (en)	2021-11-19	2023-05-24	Medizinische Hochschule Hannover	Novel sars-cov-2 neutralizing antibodies
WO2023137373A1 (en) *	2022-01-12	2023-07-20	Biomolecular Holdings Llc	Tetrahedral antibodies
WO2023140780A1 (en)	2022-01-24	2023-07-27	Aslan Pharmaceuticals Pte Ltd.	Method of treating inflammatory disease
WO2023151661A1 (zh)	2022-02-11	2023-08-17	江苏恒瑞医药股份有限公司	免疫缀合物及其用途
TW202337905A (zh)	2022-02-23	2023-10-01	新加坡商亞獅康私人有限公司	抗il13r抗體之糖基化形式
CN114657125B (zh) *	2022-04-29	2023-08-08	中国科学院海洋研究所	鲨鱼单个核细胞的分离方法、鲨鱼稀释液及其用途
WO2024038095A1 (en)	2022-08-16	2024-02-22	Iome Bio	NOVEL ANTI-RGMb ANTIBODIES
EP4590335A1 (en)	2022-08-26	2025-07-30	ASLAN Pharmaceuticals Pte Ltd	High concentration anti-il13r antibody formulation
EP4580753A1 (en)	2022-08-31	2025-07-09	Washington University	Alphavirus antigen binding antibodies and uses thereof
GB202214756D0 (en)	2022-10-07	2022-11-23	Univ Oxford Innovation Ltd	Product
GB202216284D0 (en)	2022-11-02	2022-12-14	Ucl Business Ltd	Self-regulation
CN120390651A (zh)	2022-11-28	2025-07-29	Ucb生物制药有限责任公司	纤维肌痛的治疗
JP2026502811A (ja) *	2022-12-23	2026-01-27	中外製薬株式会社	血漿タンパク質の濃度に依存して抗原に対する結合活性が変化するポリペプチド複合体
JP2026502840A (ja)	2022-12-28	2026-01-27	スゥジョウサンカディアバイオファーマシューティカルズカンパニーリミテッド	Ｃｄ４０結合分子の組成物及び医薬的使用
WO2024188331A1 (zh)	2023-03-15	2024-09-19	上海迈晋生物医药科技有限公司	一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
EP4442705A1 (en)	2023-04-03	2024-10-09	Citryll B.V.	Dosage
GB202316779D0 (en)	2023-11-01	2023-12-13	Ucl Business Ltd	Antigen binding protein
GB202318703D0 (en)	2023-12-07	2024-01-24	Citryll B V	Diagnostic agent
GB202318820D0 (en)	2023-12-08	2024-01-24	UCB Biopharma SRL	Antibodies
GB202403366D0 (en)	2024-03-08	2024-04-24	Univ Oxford Innovation Ltd	Product
WO2025196217A1 (en)	2024-03-21	2025-09-25	UCB Biopharma SRL	Treatment of tauopathies with tau-binding antibodies
WO2025238133A1 (en)	2024-05-17	2025-11-20	UCB Biopharma SRL	Multispecific antibody with binding specificity for il-11 and il-17
WO2025238135A2 (en)	2024-05-17	2025-11-20	UCB Biopharma SRL	Antibody with binding specificity for il-11

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988001649A1 (en)	1986-09-02	1988-03-10	Genex Corporation	Single polypeptide chain binding molecules
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6267964B1 (en)	1989-08-01	2001-07-31	Affibody Technology Sweden Ab	Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv)	1989-08-01	1999-01-18	Cemu Bioteknik Ab	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
JPH08500017A (ja)	1992-08-17	1996-01-09	ジェネンテク，インコーポレイテッド	二特異的免疫アドヘジン
GB9221657D0 (en)	1992-10-15	1992-11-25	Scotgen Ltd	Recombinant bispecific antibodies
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
WO1995009917A1 (en)	1993-10-07	1995-04-13	The Regents Of The University Of California	Genetically engineered bispecific tetravalent antibodies
US5972901A (en)	1994-03-23	1999-10-26	Case Western Reserve University	Serpin enzyme complex receptor--mediated gene transfer
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
ES2225961T3 (es)	1996-04-04	2005-03-16	Unilever N.V.	Proteina de union a antigeno multivalente y multiespecifica.
EP0922111B1 (en)	1996-07-23	2004-12-01	Tanox Pharma B.V.	Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
AU2152299A (en)	1997-10-27	1999-05-24	Unilever Plc	Multivalent antigen-binding proteins
ES2234241T3 (es)	1998-01-23	2005-06-16	Vlaams Interuniversitair Instituut Voor Biotechnologie	Derivados de anticuerpo de multiples fines.
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
EP1089766B1 (en)	1998-06-22	2010-03-17	Immunomedics, Inc.	Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20060228364A1 (en)	1999-12-24	2006-10-12	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
AU784285B2 (en)	1999-12-24	2006-03-02	Genentech Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
DK2857516T3 (en)	2000-04-11	2017-08-07	Genentech Inc	Multivalent antibodies and uses thereof
DE10021678A1 (de) *	2000-05-05	2002-04-18	Stefan Duebel	Antikörperkonstrukte mit variablen Regionen
US20020103345A1 (en)	2000-05-24	2002-08-01	Zhenping Zhu	Bispecific immunoglobulin-like antigen binding proteins and method of production
KR20080074231A (ko)	2000-06-29	2008-08-12	아보트 러보러터리즈	이중 특이성 항체 및 이의 제조 및 사용 방법
AU2001270609A1 (en)	2000-06-30	2002-01-14	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Heterodimeric fusion proteins
US20020010334A1 (en)	2000-06-30	2002-01-24	Xun Li	Processes to prepare pyrimidinediones
CN1461344A (zh)	2000-07-25	2003-12-10	免疫医疗公司	多价靶结合蛋白
WO2002076489A1 (en)	2001-03-09	2002-10-03	Dyax Corp.	Serum albumin binding moieties
DE60237282D1 (de)	2001-06-28	2010-09-23	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
DE60124912T2 (de)	2001-09-14	2007-06-14	Affimed Therapeutics Ag	Multimerische, einzelkettige, Tandem-Fv-Antikörper
JP2006512050A (ja)	2002-06-21	2006-04-13	ダイアックス、コープ	血清タンパク質結合標的特異的リガンドとその同定方法
EP1600459A3 (en)	2002-06-28	2005-12-07	Domantis Limited	Ligand
CA2499081A1 (en)	2002-09-16	2004-04-22	Elusys Therapeutics, Inc.	Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
JP2006520584A (ja)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	安定化単一ドメイン抗体
GB0230201D0 (en)	2002-12-27	2003-02-05	Domantis Ltd	Retargeting
CA2511910A1 (en)	2002-12-27	2004-07-15	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230203D0 (en)	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
CA2530388A1 (en)	2003-06-27	2005-01-06	Biogen Idec Ma Inc.	Modified binding molecules comprising connecting peptides
AU2004220325B2 (en)	2003-06-30	2011-05-12	Domantis Limited	Polypeptides
EP1874824A4 (en) *	2005-04-06	2009-12-30	Ibc Pharmaceuticals Inc	METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
WO2006113665A2 (en)	2005-04-15	2006-10-26	Macrogenics, Inc.	Covalent diabodies and uses thereof
EP3613767A1 (en)	2005-05-18	2020-02-26	Ablynx N.V.	Improved nanobodiestm against tumor cecrosis factor-alpha
MY169746A (en)	2005-08-19	2019-05-14	Abbvie Inc	Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
GB0601513D0 (en)	2006-01-25	2006-03-08	Univ Erasmus Medical Ct	Binding molecules 3
JP2009523460A (ja) *	2006-01-24	2009-06-25	ドマンティスリミテッド	Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
BRPI0707824A2 (pt)	2006-02-15	2011-05-10	Imclone Systems Inc	proteÍna de ligaÇço a antÍgeno, e, mÉtodos de neutralizaÇço da ativaÇço de um receptor de tirosina quinase, de inibiÇço de angiogÊnese, de reduÇço de crescimento de tumor e de produÇço de uma proteÍna de ligaÇço a antÍgeno
NZ591252A (en) *	2006-03-17	2012-06-29	Biogen Idec Inc	Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
RU2487888C2 (ru)	2006-06-12	2013-07-20	ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи	Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
CN101990439A (zh)	2007-07-06	2011-03-23	特鲁比昂药品公司	具有置于c末端的特异性结合结构域的结合肽
EP2014680A1 (en)	2007-07-10	2009-01-14	Friedrich-Alexander-Universität Erlangen-Nürnberg	Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
KR20100058509A (ko)	2007-07-31	2010-06-03	메디뮨 엘엘씨	다중특이적 에피토프 결합 단백질 및 이의 용도
ES2628395T3 (es)	2007-08-15	2017-08-02	Bayer Pharma Aktiengesellschaft	Anticuerpo regulado por proteasa
ES2667729T3 (es) *	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
AU2008328781A1 (en)	2007-11-27	2009-06-04	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009068649A2 (en)	2007-11-30	2009-06-04	Glaxo Group Limited	Antigen-binding constructs
US8227577B2 (en)	2007-12-21	2012-07-24	Hoffman-La Roche Inc.	Bivalent, bispecific antibodies
MX2010009190A (es) *	2008-02-20	2010-09-10	G2 Inflammation Pty Ltd	Anticuerpos anti-c5ar humanizados.
RU2011127198A (ru)	2008-12-04	2013-01-10	Эбботт Лэборетриз	Иммуноглобулины с двойными вариабельными доменами и их применение
PE20120540A1 (es)	2009-05-27	2012-05-09	Hoffmann La Roche	Anticuerpos triespecificos o tetraespecificos
WO2011030107A1 (en)	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products

2009
- 2009-09-25 HU HUE09736624A patent/HUE033438T2/en unknown
- 2009-09-25 EA EA201100527A patent/EA201100527A1/ru unknown
- 2009-09-25 JP JP2011528417A patent/JP6063122B2/ja not_active Expired - Fee Related
- 2009-09-25 WO PCT/GB2009/002310 patent/WO2010035012A1/en not_active Ceased
- 2009-09-25 PT PT97366249T patent/PT2334705T/pt unknown
- 2009-09-25 CN CN200980137520.4A patent/CN102164965B/zh not_active Expired - Fee Related
- 2009-09-25 US US13/121,055 patent/US10407513B2/en not_active Expired - Fee Related
- 2009-09-25 ES ES09736624.9T patent/ES2620603T3/es active Active
- 2009-09-25 LT LTEP09736624.9T patent/LT2334705T/lt unknown
- 2009-09-25 CN CN201610114944.0A patent/CN105601745B/zh not_active Expired - Fee Related
- 2009-09-25 SI SI200931626A patent/SI2334705T1/sl unknown
- 2009-09-25 CA CA2737241A patent/CA2737241C/en not_active Expired - Fee Related
- 2009-09-25 DK DK09736624.9T patent/DK2334705T3/en active
- 2009-09-25 EP EP09736624.9A patent/EP2334705B1/en active Active
- 2009-09-25 HR HRP20170374TT patent/HRP20170374T1/hr unknown
- 2009-09-25 BR BRPI0918947A patent/BRPI0918947A2/pt active Search and Examination
- 2009-09-25 PL PL09736624T patent/PL2334705T3/pl unknown
2015
- 2015-07-03 JP JP2015134223A patent/JP2015178536A/ja active Pending
2017
- 2017-03-14 CY CY20171100321T patent/CY1118713T1/el unknown
2019
- 2019-07-11 US US16/508,967 patent/US20200048372A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA201100527A1 (ru)	2011-10-31
CN105601745B (zh)	2020-09-08
EP2334705A1 (en)	2011-06-22
HUE033438T2 (en)	2017-11-28
DK2334705T3 (en)	2017-03-27
PL2334705T3 (pl)	2017-06-30
JP6063122B2 (ja)	2017-01-18
CN105601745A (zh)	2016-05-25
JP2012503638A (ja)	2012-02-09
US10407513B2 (en)	2019-09-10
LT2334705T (lt)	2017-03-27
SI2334705T1 (sl)	2017-05-31
EP2334705B1 (en)	2016-12-14
CY1118713T1 (el)	2017-07-12
HRP20170374T1 (hr)	2017-05-05
CN102164965A (zh)	2011-08-24
CA2737241C (en)	2017-08-29
PT2334705T (pt)	2017-03-22
WO2010035012A9 (en)	2011-03-17
CN102164965B (zh)	2016-03-30
CA2737241A1 (en)	2010-04-01
WO2010035012A1 (en)	2010-04-01
JP2015178536A (ja)	2015-10-08
US20110184152A1 (en)	2011-07-28
US20200048372A1 (en)	2020-02-13
ES2620603T3 (es)	2017-06-29

Publication	Publication Date	Title
BRPI0918947A2 (pt)	2015-12-01	proteína de fusão de anticorpo
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0819210A2 (pt)	2015-06-23	Anticorpos de proteína g anti-rsv
CO6491031A2 (es)	2012-07-31	Proteinas de fusion actriib-fc truncadas
IL212175B (en)	2019-08-29	Muc1* antibodies
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
EP2281845A4 (en)	2015-11-04	STABLE POLYVALENT ANTIBODY
BRPI0813452A2 (pt)	2017-05-23	protéinas de fusão rage.
BRPI0819165A2 (pt)	2015-06-23	Anticorpos anti-vegf
DK3118221T3 (da)	2019-09-23	Proteiner
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
ES2752025T8 (es)	2021-11-11	Métodos de cribado de proteínas
HUE038501T2 (hu)	2018-10-29	Antitest készítmények
EP2254911A4 (en)	2011-10-19	HUMANIZED ANTI-C5aR ANTIBODIES
DK2131860T3 (da)	2014-01-13	Anti-sclerostin-antistoffer
BRPI0820073A2 (pt)	2015-06-23	Anticorpos anti-axl
DK2307543T3 (da)	2015-08-31	Forbedret proteinekspressionssystem
PT2195026E (pt)	2014-03-31	Anticorpos anti-esclerostina
EP2403941A4 (en)	2012-09-05	Stabilized reverse transcriptase fusion proteins
BRPI0716744A2 (pt)	2016-10-04	proteínas de fusão de albumina
DK2046826T3 (da)	2011-10-24	Exendin-fusionsproteiner
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
HRP20150241T1 (xx)	2015-06-05	Antikancerogeni fuzijski protein

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2019-12-03	B07E	Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-02-27	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-04-20	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-08-03	B11D	Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time